Cellectar Biosciences, Inc. (CLRB) Announces Corporate Highlights and Financial Results for Q2 2016
Cellectar Biosciences, Inc. (NASDAQ: CLRB) recently announced (http://nnw.fm/I70Ox) its corporate highlights for this quarter and financial results for Q2 2016, which ended on June 30 of this year. One of the company’s key accomplishments was the issuance of several patents from USPTO, including CLR 131 and other radiotherapeutics used in the treatment of cancerous cells, as well as the CLR 1600 series. In addition to these, the company shared the results of its preclinical study of 1602, and announced the completion of the first phase of the NCI SBIR fast track grant. CLRB also closed $8 million in financing and…